RQM+ has launched its clinical trial services division to complete its full complement of MedTech contract research organization (CRO) services.

Building upon 40 years of regulatory and quality expertise, RQM+ now offers comprehensive laboratory testing, product development, reimbursement strategy and clinical trial services to support the entire product lifecycle for medical devices, digital therapeutics and diagnostics.

David Novotny, CEO for trial services, RQM+

“We have fully evolved our capabilities to become the MedTech partner of choice for clients who want to reduce their commercialization risk by providing all the services needed to launch their products in the market and keep them there,” said Margaret Keegan, CEO. “With the strongest regulatory consulting team in the MedTech industry, our trusted experts provide support from the early development stage to commercialization, all within one organization. To deliver the high-quality clinical trials our clients expect, we are delighted to have someone with the depth of expertise that David Novotny brings to lead our trial services business.”

Novotny, chief operating officer for trial services, has more than 20 years of MedTech clinical trial leadership experience in trial operations, consulting and device research across North America, Europe and Asia-Pacific. He previously held strategic leadership positions managing all trial services for several global MedTech CROs.
RQM+ currently works for eight of the top 10 medical device manufacturers and seven of the top 10 IVD companies.

For more information, visit RQMplus.com.

Digital issue: Please click here for more information